Barclays Maintains an 'Overweight' on Thoratec (THOR); Docs Have Noticed PHP; Maybe It's Time Investors Did, Too
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Thoratec (NASDAQ: THOR), PT $39.
Barclays analyst says, "We recently had the opportunity to attend ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We recently had the opportunity to attend ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
